Proficio Capital Partners LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Proficio Capital Partners LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 2,193.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 225,584 shares of the biopharmaceutical company’s stock after buying an additional 215,747 shares during the period. Proficio Capital Partners LLC’s holdings in Pfizer were worth $5,985,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Mn Services Vermogensbeheer B.V. boosted its holdings in shares of Pfizer by 2.1% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 2,230,300 shares of the biopharmaceutical company’s stock valued at $59,170,000 after acquiring an additional 46,200 shares during the last quarter. New York Life Investment Management LLC boosted its holdings in Pfizer by 1.2% in the fourth quarter. New York Life Investment Management LLC now owns 786,520 shares of the biopharmaceutical company’s stock valued at $20,866,000 after purchasing an additional 9,007 shares during the last quarter. Allegiance Financial Group Advisory Services LLC acquired a new stake in Pfizer during the 4th quarter worth about $231,000. Cable Hill Partners LLC raised its stake in shares of Pfizer by 20.5% during the 4th quarter. Cable Hill Partners LLC now owns 21,344 shares of the biopharmaceutical company’s stock valued at $566,000 after buying an additional 3,632 shares during the last quarter. Finally, Whipplewood Advisors LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $108,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Truist Financial reduced their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Guggenheim restated a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Down 0.8 %

Shares of PFE opened at $26.21 on Tuesday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a market cap of $148.53 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm’s fifty day moving average is $26.34 and its two-hundred day moving average is $27.30. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.56%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is presently 121.99%.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.